Rapid Screen for Genotoxicants, Chemoprotectors, and Radioprotectors

快速筛查基因毒物、化学保护剂和放射保护剂

• 批准号: 7107411
• 负责人: STEPHEN D DERTINGER
• 金额: $ 13.33万
• 依托单位: LITRON LABORATORIES, LTD.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7107411
• 关键词: biological response modifiers; micronucleus; miniature biomedical equipment; neoplasm /cancer; stainings

DESCRIPTION (provided by applicant): This research project addresses an important problem faced by the chemical and drug industries? their requirement to evaluate the DNA damaging potential of ever larger numbers of new chemical entities in shorter periods of time. This situation presents opportunities for small businesses that are able to provide solutions to these challenges. The work proposed herein addresses industry's need for higher throughput toxicity assessment through the development of an automated in vitro chromosomal damage assay. Chromosome damage will be quantified by flow cytometric micronucleus measurements. Importantly, the methodology that will be developed over the course of this project not only represents a high volume genotoxicant screening system, but also one that can be configured to identify agents which protect against chromosomal damage. This project addresses a stated need of investigators working to develop the next generation of biological response modifiers (BRMs). BRMs that provide chemo- or radio-protection hold great promise in several important arenas, including cancer treatments which are typically dose-limited by normal tissue responses. The identification and development of BRMs have other important applications, and include enhanced protection of our troops during times of war, and also for civilian victims of chemical or radiological terrorist attacks. The planned Phase 1 and Phase 2 efforts have thus been designed to provide a rapid and efficient assay for detecting the genotoxicant, radioprotectant, or chemoprotectant potential of test chemicals. This screening assay will help chemical and drug companies allocate their resources to the most promising candidates, eliminating hazardous entities early in development. Furthermore, by aiding in the identification of next generation BRMs, cancer patients and armed forces will benefit from the availability of chemo- and radio-protectant drugs.

描述（由申请人提供）：该研究项目解决了化学和药物工业面临的一个重要问题？他们需要在更短的时间内评估越来越多的新化学实体的DNA损伤潜力。这种情况为能够为这些挑战提供解决方案的小企业提供了机会。本文提出的工作通过开发自动化体外染色体损伤测定来解决工业对更高通量毒性评估的需求。将通过流式细胞仪微核测量定量染色体损伤。重要的是，将在本项目过程中开发的方法不仅代表了高容量遗传毒性筛选系统，而且还可以配置为识别防止染色体损伤的药物。该项目致力于开发下一代生物反应调节剂（BRM）的研究人员的需求。提供化疗或放射保护的BRM在几个重要领域具有很大的前景，包括通常受正常组织反应剂量限制的癌症治疗。生物放射性物质的识别和开发还有其他重要的应用，包括在战争期间加强对我们部队的保护，以及保护化学或放射性恐怖袭击的平民受害者。因此，计划的I期和II期研究旨在提供一种快速有效的试验方法，用于检测供试化学品的遗传毒性、辐射防护或化学防护潜力。这种筛选分析将帮助化学和制药公司将其资源分配给最有前途的候选人，在开发早期消除危险实体。此外，通过帮助识别下一代BRM，癌症患者和武装部队将受益于化疗和放射保护药物的可用性。